Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have received an average rating of “Moderate Buy” from the twenty analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $31.44.

A number of analysts have recently commented on EXEL shares. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Exelixis in a research note on Wednesday, October 30th. Piper Sandler boosted their price target on shares of Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Guggenheim raised their price objective on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Truist Financial boosted their target price on shares of Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, UBS Group began coverage on shares of Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price for the company.

Insider Activity at Exelixis

In related news, EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. The trade was a 16.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George Poste sold 30,000 shares of Exelixis stock in a transaction on Friday, November 1st. The shares were sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the sale, the director now directly owns 169,020 shares of the company’s stock, valued at $5,746,680. This trade represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,148 shares of company stock valued at $8,042,547. Company insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter valued at approximately $30,000. Brooklyn Investment Group bought a new stake in Exelixis in the third quarter worth approximately $42,000. Park Place Capital Corp acquired a new position in shares of Exelixis during the 2nd quarter worth $45,000. GAMMA Investing LLC raised its holdings in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC raised its holdings in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,746 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Down 1.7 %

EXEL stock opened at $34.45 on Friday. The company has a market capitalization of $9.84 billion, a P/E ratio of 22.08, a PEG ratio of 0.89 and a beta of 0.51. The company has a 50-day simple moving average of $29.04 and a 200 day simple moving average of $25.14. Exelixis has a fifty-two week low of $19.20 and a fifty-two week high of $36.60.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. During the same period in the prior year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. Equities analysts anticipate that Exelixis will post 1.68 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.